Ph 2 results from LTX-315 skin cancer (BCC) trial show an 86% overall reduction of tumor size, complete clearance in half of the patients

“Together with our partner Verrica, we’re immensely proud of these results, showing that our lead drug candidate LTX-315 has a powerful anticancer effect in basal cell carcinoma. It has the potential to be used either alone or in combination with surgery in early lines of treatment in this vast cancer population. This is a major leap for our unique treatment technology and an instrumental milestone in progressing LTX-315 towards commercialization”, says Dr. Øystein Rekdal, CEO of Lytix Biopharma.

Share:

More News

CEO Snehal Patel commented, “We are very encouraged to see that the preliminary results from FLAMINGO-01 show immune responses in both HLA-A*02 and non-HLA-A*02 patients. We are now considering the merits of adding a randomized placebo arm for non-HLA-A*02 patients, transforming this current open label third arm into effectively a

“At Ferring, we are committed to meeting the unmet needs in bladder cancer care and equipping uro-oncologists with critical evidence they need to deliver effective, and life-changing treatment,” said Joern Jakobsen, M.D., Ph.D., Vice President and Head of Global Research and Medical for Uro-Oncology and Urology, Ferring Pharmaceuticals. “These new

“We recognise the significance of Mosaic’s platform, which has identified these two assets as anchor components of a pipeline of potential combination products,” said Dr. Harren Jhoti, co-founder, president and chief executive officer of Astex. “Both drug targets are well-characterised drivers of many cancers, and we are excited to be

“We do not view today’s unsatisfactory outcome as a failure of Globo H,” Dr. Heidi Wang, CEO of OBI Pharma added. “There may come a time, with a deeper scientific understanding of the Globo H function, it may play a meaningful role once again.”